1. Home
  2. SHOT vs INKT Comparison

SHOT vs INKT Comparison

Compare SHOT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHOT
  • INKT
  • Stock Information
  • Founded
  • SHOT 2018
  • INKT 2017
  • Country
  • SHOT United States
  • INKT United States
  • Employees
  • SHOT N/A
  • INKT N/A
  • Industry
  • SHOT Biotechnology: Pharmaceutical Preparations
  • INKT Medicinal Chemicals and Botanical Products
  • Sector
  • SHOT Health Care
  • INKT Health Care
  • Exchange
  • SHOT Nasdaq
  • INKT Nasdaq
  • Market Cap
  • SHOT 83.7M
  • INKT 69.2M
  • IPO Year
  • SHOT 2020
  • INKT 2021
  • Fundamental
  • Price
  • SHOT $0.30
  • INKT $14.24
  • Analyst Decision
  • SHOT
  • INKT Buy
  • Analyst Count
  • SHOT 0
  • INKT 3
  • Target Price
  • SHOT N/A
  • INKT $37.50
  • AVG Volume (30 Days)
  • SHOT 3.6M
  • INKT 45.1K
  • Earning Date
  • SHOT 11-13-2025
  • INKT 11-13-2025
  • Dividend Yield
  • SHOT N/A
  • INKT N/A
  • EPS Growth
  • SHOT N/A
  • INKT N/A
  • EPS
  • SHOT N/A
  • INKT N/A
  • Revenue
  • SHOT N/A
  • INKT N/A
  • Revenue This Year
  • SHOT N/A
  • INKT N/A
  • Revenue Next Year
  • SHOT N/A
  • INKT N/A
  • P/E Ratio
  • SHOT N/A
  • INKT N/A
  • Revenue Growth
  • SHOT 246.36
  • INKT N/A
  • 52 Week Low
  • SHOT $0.23
  • INKT $4.56
  • 52 Week High
  • SHOT $1.77
  • INKT $76.00
  • Technical
  • Relative Strength Index (RSI)
  • SHOT 33.77
  • INKT 47.11
  • Support Level
  • SHOT $0.30
  • INKT $13.11
  • Resistance Level
  • SHOT $0.45
  • INKT $16.20
  • Average True Range (ATR)
  • SHOT 0.04
  • INKT 1.13
  • MACD
  • SHOT -0.00
  • INKT -0.01
  • Stochastic Oscillator
  • SHOT 1.11
  • INKT 35.38

About SHOT Safety Shot Inc.

Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Share on Social Networks: